论文标题：Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

期刊： Frontiers of Medicine

作者：Ziyu Fu, Dongguo Liang, Wei Zhang, Dongling Shi, Yuhua Ma, Dong Wei, Junxiang Xi, Sizhe Yang, Xiaoguang Xu, Di Tian, Zhaoqing Zhu, Mingquan Guo, Lu Jiang, Shuting Yu, Shuai Wang, Fangyin Jiang, Yun Ling, Shengyue Wang, Saijuan Chen, Feng Liu, Yun Tan, Xiaohong Fan

发表时间：15 Jun 2023

DOI：10.1007/s11684-022-0977-3

微信链接：点击此处阅读微信文章

导 读

上海交通大学医学院附属瑞金医院陈赛娟、刘峰、谭云和复旦大学上海市公共卫生临床中心范小红等在Frontiers of Medicine发表研究论文《2022年春季上海新冠疫情中，既往疫苗接种对奥密克戎BA.2.2亚谱系的宿主保护作用》（Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai）。本研究通过分析2022年春季上海奥密克戎BA.2.2亚谱系疫情中9911例有症状感染患者的临床数据，发现接种2-3剂基于原型毒株的灭活疫苗可显著抑制重症/危重症COVID-19，并揭示了BA.2.2感染后肺泡微环境中促炎巨噬细胞活性降低、干扰素α反应增强等独特的病理特征，表明疫苗可以通过调节免疫反应减轻器官损伤和炎症风暴，为老年人群等高危群体的免疫策略提供了证据。

The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≥ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines.

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变异株家族推动新冠疫情发展。本研究分析了2022年春季上海新冠疫情期间9911名感染奥密克戎BA.2.2亚谱系且无早期感染史的有症状患者的临床实验室检测结果。与2020年感染SARS-CoV-2原始毒株的早期患者相比，BA.2.2感染导致外周血中病理生理标志物出现了明显的波动。特别是，感染BA.2.2后出现的新冠重症/危重症病例与支气管肺泡微环境中促炎性巨噬细胞的激活程度较低以及I型干扰素反应较强相关。值得注意的是，在接种过2剂/3 剂SARS-CoV-2原始毒株灭活疫苗的个体中，异常的生物标志物显著降低，这支持了在可追溯疫苗接种记录的4854例BA.2.2患者中，对重症/危重症疾病总体保护率为96.02%的评估。此外，尽管年龄是感染BA.2.2后新冠病情严重程度的一个关键风险因素，但在60岁及以上患者中，疫苗接种形成的对重症/危重症新冠的保护率达到了90.15%。综上所述，本研究阐明了奥密克戎BA.2.2亚谱系的病理生理特征，并证实基于原始毒株的灭活疫苗能提供显著的保护效力。

期刊介绍

Frontiers of Medicine专注于发表临床医学和基础医学领域的最新研究成果，旨在通过全球医疗专业人员之间的交流促进健康和医疗保健的发展。该刊采用严格的同行评审和编辑流程，确保发表的文章的科学准确性、新颖性和重要性。

原文信息

标题

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

作者

Ziyu Fu¹, Dongguo Liang¹, Wei Zhang^1,2, Dongling Shi³, Yuhua Ma⁴, Dong Wei⁵, Junxiang Xi¹, Sizhe Yang¹, Xiaoguang Xu¹, Di Tian³, Zhaoqing Zhu³, Mingquan Guo³, Lu Jiang¹, Shuting Yu¹, Shuai Wang¹, Fangyin Jiang¹, Yun Ling³, Shengyue Wang¹, Saijuan Chen¹, Feng Liu¹, Yun Tan¹, Xiaohong Fan³

机构

1. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai 200025, China

2. National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi’an 710032, China

3. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

4. Department of Nephrology, Traditional Chinese Medicine Hospital of KunShan, Suzhou 215300, China

5. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai 200025, China

通讯作者

Saijuan Chen, Feng Liu, Yun Tan, Xiaohong Fan

引用这篇文章

Ziyu Fu, Dongguo Liang, Wei Zhang, Dongling Shi, Yuhua Ma, Dong Wei, Junxiang Xi, Sizhe Yang, Xiaoguang Xu, Di Tian, Zhaoqing Zhu, Mingquan Guo, Lu Jiang, Shuting Yu, Shuai Wang, Fangyin Jiang, Yun Ling, Shengyue Wang, Saijuan Chen, Feng Liu, Yun Tan, Xiaohong Fan. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front. Med., 2023, 17(3): 562–575

https://doi.org/10.1007/s11684-022-0977-3

https://journal.hep.com.cn/fmd/EN/10.1007/s11684-022-0977-3

https://link.springer.com/article/10.1007/s11684-022-0977-3

感谢作者对Frontiers of Medicine的信任和支持。

《前沿》系列英文学术期刊

由教育部主管、高等教育出版社主办的《前沿》（Frontiers）系列英文学术期刊，于2006年正式创刊，以网络版和印刷版向全球发行。系列期刊包括基础科学、生命科学、工程技术和人文社会科学四个主题，是我国覆盖学科最广泛的英文学术期刊群，其中12种被SCI收录，其他也被A&HCI、Ei、MEDLINE或相应学科国际权威检索系统收录，具有一定的国际学术影响力。系列期刊采用在线优先出版方式，保证文章以最快速度发表。

中国学术前沿期刊网

http://journal.hep.com.cn